A historic milestone has been achieved in the field of longevity research, as the first-ever reverse-aging drug has been injected into a human. This groundbreaking therapy, designed to reset the epigenetic clock and reverse cellular aging, aims to combat age-related sight loss. The startup Life Biosciences has announced successful dosing of the first patient in a Phase 1 trial of ER-100, specifically targeting optic neuropathies. This momentous step signifies not only a significant advancement for the affected patient but also a promising leap forward for the future of age-reversing therapies.